HK1253901A1 - 治療或預防急性腦或神經損傷的方法 - Google Patents

治療或預防急性腦或神經損傷的方法

Info

Publication number
HK1253901A1
HK1253901A1 HK18113049.4A HK18113049A HK1253901A1 HK 1253901 A1 HK1253901 A1 HK 1253901A1 HK 18113049 A HK18113049 A HK 18113049A HK 1253901 A1 HK1253901 A1 HK 1253901A1
Authority
HK
Hong Kong
Prior art keywords
prevention
treatment
methods
acute brain
nerve injuries
Prior art date
Application number
HK18113049.4A
Other languages
English (en)
Inventor
Maria Maccecchini
Original Assignee
Qr Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qr Pharma filed Critical Qr Pharma
Publication of HK1253901A1 publication Critical patent/HK1253901A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18113049.4A 2015-08-14 2018-10-12 治療或預防急性腦或神經損傷的方法 HK1253901A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562205431P 2015-08-14 2015-08-14
PCT/US2016/046794 WO2017030968A1 (en) 2015-08-14 2016-08-12 Methods of treatment or prevention of acute brain or nerve injuries

Publications (1)

Publication Number Publication Date
HK1253901A1 true HK1253901A1 (zh) 2019-07-05

Family

ID=56801810

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113049.4A HK1253901A1 (zh) 2015-08-14 2018-10-12 治療或預防急性腦或神經損傷的方法

Country Status (10)

Country Link
US (1) US20180228771A1 (zh)
EP (1) EP3334425B1 (zh)
JP (1) JP6862446B2 (zh)
CN (1) CN107921024B (zh)
AU (1) AU2016309815B2 (zh)
CA (1) CA2994974C (zh)
DK (1) DK3334425T3 (zh)
HK (1) HK1253901A1 (zh)
TW (1) TW201717938A (zh)
WO (1) WO2017030968A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3654957A4 (en) * 2017-05-24 2021-06-23 Annovis Bio, Inc. PREVENTION OR TREATMENT OF DISEASE CONDITIONS DUE TO METAL DIS-HOMEOSTASIS BY ADMINISTERING POSIPHES TO HEALTHY OR SICK PEOPLE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171750A (en) * 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
JP2003525903A (ja) * 2000-03-03 2003-09-02 エーザイ株式会社 コリンエステラーゼ阻害剤の新規使用法
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20120225922A1 (en) * 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration

Also Published As

Publication number Publication date
EP3334425A1 (en) 2018-06-20
US20180228771A1 (en) 2018-08-16
EP3334425B1 (en) 2020-12-16
CA2994974C (en) 2024-04-09
CN107921024B (zh) 2021-09-10
JP2018523709A (ja) 2018-08-23
DK3334425T3 (da) 2021-02-22
AU2016309815B2 (en) 2022-04-07
CN107921024A (zh) 2018-04-17
CA2994974A1 (en) 2017-02-23
JP6862446B2 (ja) 2021-04-21
AU2016309815A1 (en) 2018-02-15
WO2017030968A1 (en) 2017-02-23
TW201717938A (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
HK1257321A1 (zh) 用於治療腦組織的組織摧毀術治療系統和方法
IL293712A (en) Methods for treating mild brain injury
IL255185A0 (en) 1-Heteroaryl-indoline-4-carboxamides as gpr52 modulators for treatment or prevention of related disorders
IL251262A0 (en) Methods for treating traumatic brain injury
SG11201700530PA (en) Agent for improving brain function and agent for preventing or treating cognitive impairment
IL249439A0 (en) A compound and method for the treatment of neurological diseases and brain injury
HK1245127A1 (zh) 治療腦疾病的方法和組合物
HK1249865B (zh) 疼痛的治療
IL250658A0 (en) Methods for treating mild brain injury
ZA201806807B (en) Method for the treatment or prevention of osteoarthritis
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL263080B (en) Treatment of neurological disorders
HK1252796A1 (zh) 用於周圍神經病症或脊髓損傷的治療劑和/或預防劑
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
GB201602802D0 (en) Method of treatment
HK1253901A1 (zh) 治療或預防急性腦或神經損傷的方法
EP3377062C0 (en) AMINONAPHHOQUINONE COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES
PL3717011T3 (pl) Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu
EP3416977A4 (en) TREATMENT OF TRAUMATIC BRAIN INJURY OR IMPACT
GB201512139D0 (en) Methods of treatment
GB201522828D0 (en) Prevention and treatment of glaucoma
GB201602011D0 (en) Treating skin disorders
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases